Abstract
BackgroundAs highly sensitive liquid biopsy assays have been developed, minimal residual disease (MRD) has emerged as a novel tool to predict the prognosis of cancer patients.1 Monitoring MRD during post-curative-intent...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
